Sign up
Pharma Capital

Race Oncology Ltd targets cash injection following research joint venture

The halt will remain in place until Monday 17th July 2017.
australian-dollar757.jpg
Race Oncology is focused on cancer therapies

Race Oncology Ltd (ASX:RAC) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.

The company recently executed a Letter of Intent with TargImmune Therapeutics AG to enter into a joint venture between the two companies.

The joint venture, to be called Race Immunotherapeutics, will focus on developing new and improved cancer therapies based on combining Bisantrene with TargImmune’s targeted cancer therapy technology.

The halt will remain in place until the opening of trade on Monday 17th July 2017, or earlier if an announcement is made to the market.



Register here to be notified of future RAC Company articles
View full RAC profile

Race Oncology Ltd Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.